Clinseq_AML

<p>This dataset is used in study "Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling". The original study is published on Leukemia (M Wang, J Lindberg, D Klevebring, C Nilsson, A S Mer, M Rantalainen, S Lehmann and H Grönberg. Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling. Leukemia advance online publication 10 March 2017; doi: 10.1038/leu.2017.48).</p> <p> </p> <p>It includes demographic information, somatic mutations, normalized RNA sequencing counts, and derived prognostic scores of 274 patients diagnosed with acute myeloid leukemia. </p> <p> </p> <ul> <li>sex: Sex (M = male, F = female)</li> <li>age:     Age at diagnosis</li> <li>aml_etiology:  de novo = AML without any any antecedent causative disease or treatment, s-AML = AML following and antecedent hematological disorder such as MDS, MPN or aplastic anemia, t-AML = AML following radiation or cytotoxic drugs (patients treated with cytotoxic therapy for MDS/MPN are considered s-AML)</li> <li>OS: overall survival (days)</li> <li>status: Vital status (0 = alive, 1 = deceased)</li> <li>cytogenetic risk: cytogenetic risk classification</li> <li>ELN: the European LeukemiaNet (ELN) risk classification</li> <li>FLT3_ITD, DNMT3A, IDH1, IDH2_140, TET2, TP53, RUNX1, NRAS, CEBPA, WT1, KIT, ASXL1, PHF6, KRAS, PTEN, EZH2, PTPN11, U2AF1, SRSF2, SF3B1, STAG2, SMC1A, SMC3, RAD21, NPM1, IDH2_172, FLT3_HS, CEBPA2: somatic mutation (0 = wild type, 1 = mutated)</li> <li>ENSG***********: normalized RNA sequencing counts. Details about bioinformatics processing were described in Supplementary Methods of the publication.</li> <li>Derived prognostic scores: Details were described in the publication.</li> </ul> <p> </p> <p> </p>